Business Description
Beam Therapeutics Inc
NAICS : 325411
SIC : 2833
ISIN : US07373V1052
Description
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 6.1 | |||||
Equity-to-Asset | 0.68 | |||||
Debt-to-Equity | 0.19 | |||||
Debt-to-EBITDA | -1.01 | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 2.15 | |||||
Beneish M-Score | 0.46 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 1598 | |||||
3-Year EBITDA Growth Rate | 9.5 | |||||
3-Year EPS without NRI Growth Rate | 15.7 | |||||
3-Year FCF Growth Rate | 0.4 | |||||
3-Year Book Growth Rate | 41 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate | -32.52 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | -43.49 |
Momentum Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 72.1 | |||||
9-Day RSI | 60.15 | |||||
14-Day RSI | 54.72 | |||||
6-1 Month Momentum % | 1.21 | |||||
12-1 Month Momentum % | -4.41 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 5.81 | |||||
Quick Ratio | 5.81 | |||||
Cash Ratio | 5.69 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -12.6 | |||||
Shareholder Yield % | -3.07 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -52.31 | |||||
Net Margin % | -40.56 | |||||
FCF Margin % | -43.51 | |||||
ROE % | -16.48 | |||||
ROA % | -10.63 | |||||
ROIC % | -46.19 | |||||
3-Year ROIIC % | -28.81 | |||||
ROC (Joel Greenblatt) % | -78.55 | |||||
ROCE % | -16.11 |
GF Value Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 5.57 | |||||
PB Ratio | 2.31 | |||||
Price-to-Tangible-Book | 2.31 | |||||
EV-to-EBIT | -6.49 | |||||
EV-to-Forward-EBIT | -3.76 | |||||
EV-to-EBITDA | -7.35 | |||||
EV-to-Forward-EBITDA | -3.36 | |||||
EV-to-Revenue | 3.4 | |||||
EV-to-Forward-Revenue | 17.13 | |||||
EV-to-FCF | -7.59 | |||||
Price-to-Net-Current-Asset-Value | 3.17 | |||||
Price-to-Net-Cash | 3.28 | |||||
Earnings Yield (Greenblatt) % | -15.41 | |||||
FCF Yield % | -7.78 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:BEAM
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Beam Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 352.567 | ||
EPS (TTM) ($) | -1.81 | ||
Beta | 2.07 | ||
Volatility % | 94.78 | ||
14-Day RSI | 54.72 | ||
14-Day ATR ($) | 1.219958 | ||
20-Day SMA ($) | 23.482 | ||
12-1 Month Momentum % | -4.41 | ||
52-Week Range ($) | 18.8501 - 49.5 | ||
Shares Outstanding (Mil) | 82.42 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 5 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Beam Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Beam Therapeutics Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Beam Therapeutics Inc Frequently Asked Questions
What is Beam Therapeutics Inc(BEAM)'s stock price today?
When is next earnings date of Beam Therapeutics Inc(BEAM)?
Does Beam Therapeutics Inc(BEAM) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |